DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



High Dose Versus Standard Dose Proton Pump Inhibitor (PPI) in High-Risk Bleeding Peptic Ulcers After Combined Endoscopic Treatment

Information source: National Taiwan University Hospital
Information obtained from ClinicalTrials.gov on October 19, 2009
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Endoscopy; Peptic Ulcer; Bleeding; Proton Pump Inhibitors

Intervention: High dose pantoprazole infusion (Drug); Standard dose pantoprazole infusion (Drug)

Phase: N/A

Status: Recruiting

Sponsored by: National Taiwan University Hospital

Overall contact:
Chieh-Chang Chen, MD, Phone: 886-5-532-3911, Ext: 2200, Email: chiehchang.chen@gmail.com

Summary

The study was designed to evaluate the efficacy an adjuvant use of standard dose or high dose of proton pump inhibitor after combined endoscopic hemostasis therapy.

Clinical Details

Official title: High Dose Versus Standard Dose Proton Pump Inhibitor in High-Risk Bleeding Peptic Ulcers After Endoscopic Epinephrine Injection and Heat Probe Thermocoagulation/Hemo-Clip Hemostasis: A Prospective Randomized Comparative Study

Study design: Treatment, Randomized, Single Blind (Subject), Dose Comparison, Parallel Assignment, Safety/Efficacy Study

Primary outcome: rate of initial hemostasis and the rate of recurrent bleeding

Secondary outcome: need for surgical intervention to control bleeding, transfusion requirements, length of hospital stay (in days), and 30-day mortality

Detailed description: Acute peptic ulcer bleeding remains the most common cause of acute upper gastrointestinal bleeding. Endoscopy serves as a tool for initial diagnosis and triage and also a tool for immediate hemostasis, especially for high-risk lesions. High-risk lesions include peptic ulcers with active spurting vessel, oozing vessel, or NBVV, nonbleeding visible vessel. Current modalities of endoscopic hemostasis include epinephrine injection, endoscopic coaptive thermocoagulation, hemoclipping. Endoscopic hemostasis has been documented by a number of clinical studies to be effective in decreasing rebleeding, need for emergency surgery, decreasing hospitalization days. Current evidence also shows that combination therapy with epinephrine injection and heater probe thermocoagulation/hemo-clip hemostasis is more effective than epinephrine injection alone or than heater probe thermocoagulation alone, or than hemoclip hemostasis alone. Studies showed a high dose intravenous proton pump inhibitor infusion after initial endoscopic hemostasis reduced recurrent ulcer bleeding. However, it was still controversial whether an adjuvant use of standard-dose proton pump inhibitor therapy to endoscopic therapy had similar benefit. We hypothesized that an adjuvant use of standard dose of proton pump inhibitor after combined endoscopic hemostasis therapy offer similar benefit as high dose proton pump inhibitor did.

Eligibility

Minimum age: 16 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- adults aged above 16 years old with acute nonvariceal upper gastrointestinal bleeding

- read, agree to attend the study, and signed informed consent indicated to receive

esophagogastroduodenoscopy(EGD)

- peptic ulcers with high risk lesions (active bleeding: spurting, oozing peptic

ulcers. Ulcers with NBVV: nonbleeding visible vessel)

Exclusion Criteria:

- unable to receive EGD (unable to open mouth, upper gastrointestinal obstruction)

- bleeding tendency (platelet < 50x109/L, prothrombin time INR >2, ongoing use of

heparin or coumadin)

- gastric malignancy

- myocardial infarction within recent one week

- recent cerebrovascular event within recent one week

- pregnancy

- refuse to attend the study

- known allergy history to epinephrine or pantoprazole

Locations and Contacts

Chieh-Chang Chen, MD, Phone: 886-5-532-3911, Ext: 2200, Email: chiehchang.chen@gmail.com

National Taiwan University Hospital, Taipei, Taiwan; Recruiting
Chieh-Chang Chen, MD, Phone: 886-5-532-3911, Ext: 2200, Email: chiehchang.chen@gmail.com
Additional Information

Starting date: January 2008
Last updated: July 2, 2008

Page last updated: October 19, 2009

-- advertisement -- The American Red Cross
We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2009